



## UTILITY PATENT APPLICATION TRANSMITTAL

*Submit an original and a duplicate for fee processing  
Only for new nonprovisional applications under 37 CFR §1.53(b))*

Attorney Docket No.	213187
First Inventor	KOVESDI, Imre
Title	ADENOVECTOR PHARMACEUTICAL COMPOSITION
Express Mail No.	EF125999585US



### APPLICATION ELEMENTS

1.  Utility Patent Application Transmittal Form
2.  Applicant claims small entity status.  
See 37 CFR 1.27.
3.  Specification (including claims and abstract) [Total Pages 41]
4.  Drawings [Total Sheets 4]
5.  Combined Declaration and Power of Attorney [Total Pages 4]
  - a.  Unexecuted
  - b.  Copy from prior application [Note Box 6 below]
    - i.  Deletion of Inventor(s) Signed statement attached deleting inventor(s) named in the prior application
6.  Incorporation by Reference: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b is considered as part of the disclosure of the accompanying application and is hereby incorporated by reference.
7.  Application Data Sheet. See 37 CFR 1.76
8.  CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
9. Nucleotide and/or Amino Acid Sequence Submission
  - a.  Computer Readable Form (CRF)
  - b. Specification Sequence Listing on:
    - i.  CD-ROM or CD-R (2 copies); or
    - ii.  Paper Copy
  - c.  Statement verifying identity of above copies

ADDRESS  
TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

### ACCOMPANYING APPLICATION PARTS

10.  Applicant requests early publication. (include publication fee under 37 CFR 1.18(d))
11.  Assignment Papers (cover sheet and document(s))
12.  37 CFR 3.73(b) Statement (when there is an Assignee)
13.  Power of Attorney
14.  English Translation Document (if applicable)
15.  Information Disclosure Statement (IDS)
  - Form PTO-1449
  - Copies of Listed Documents
16.  Preliminary Amendment
17.  Return Receipt Postcard (Should be specifically itemized)
18.  Certified Copy of Priority Document(s)
19.  Request & Certification Under 35 USC 122(b)(2)(B)(i) (Form PTO/SB/35 or its equivalent attached)
20.  Other:
 

Amendments to Specification and Claims Made via Preliminary Amendment.  
Pending Claims After Entry of Preliminary Amendment.  
Submission of Formal Drawings.


21. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information in (a) and (b) below:

- (a)  Continuation  Divisional  Continuation-in-part of prior Application No. 08/258,416, filed on June 10, 1994, which is incorporated by reference.  
Prior application information: Examiner: Scott D. Priebe; Group Art Unit: 1632.
- (b) Preliminary Amendment: Benefit of earlier filing date - 35 USC 120. The Commissioner is requested to amend the specification by inserting the following sentence before the first line:  
"This is a  continuation  divisional  continuation-in-part (CIP) of  
 Application No. , filed on , which is incorporated by reference."  
 International Application No. , filed on , which designates the U.S., and which is incorporated by reference."

UTILITY PATENT APPLICATION TRANSMITTAL			Attorney Docket No.	213187
APPLICATION FEES				
BASIC FEE				\$ 710.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	20 - 20 =	0	x \$18.00	\$ 0.00
Independent Claims	1 - 3 =	0	x \$80.00	\$ 0.00
<input type="checkbox"/> Multiple Dependent Claim if applicable				+\$270.00
				\$ 0.00
				Total of above calculations =
				\$ 710.00
				Reduction by 50% for filing by small entity =
<input type="checkbox"/> Assignment fee if applicable				+ \$40.00
<input type="checkbox"/> Early publication fee if applicable				+ \$300.00
				<b>TOTAL =</b>
				<b>\$ 710.00</b>

22.  Please charge my Deposit Account No. 12-1216 in the amount of \$ 710.00.
23.  A check in the amount of \$ \_\_\_\_\_ is enclosed.
24. The Commissioner is hereby authorized to credit overpayments or charge any additional fees of the following types to Deposit Account No. 12-1216:
- Fees required under 37 CFR 1.16.
  - Fees required under 37 CFR 1.17.
25.  The Commissioner is hereby generally authorized under 37 CFR 1.136(a)(3) to treat any future reply in this or any related application filed pursuant to 37 CFR 1.53 requiring an extension of time as incorporating a request therefor, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 12-1216 for any fee that may be due in connection with such a request for an extension of time.

26. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number: 23460  <b>23460</b> <small>PATENT TRADEMARK OFFICE</small>		<input type="checkbox"/> , Reg. No. Leydig, Voit & Mayer, Ltd. Two Prudential Plaza, Suite 4900 180 North Stetson Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)
Name	John Kilyk, Jr., Registration No. 30,763	
Signature		
Date	August 21, 2001	

Certificate of Mailing Under 37 CFR 1.10

I hereby certify that this Utility Patent Application Transmittal and all accompanying documents are being deposited with the United States Postal Service "Express Mail Post Office To Addressee" Service under 37 CFR 1.10 on the date indicated below and is addressed to: Assistant Commissioner of Patents, Box Patent Application, Washington, D.C. 20231.

Peter Phillips Name of Person Signing		August 21, 2001 Date
--	---	-------------------------

Utility (Rev. 11/13/2000)

**PATENT**

Attorney Docket No. 213187

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Kovesdi et al.

Group Art Unit: Unassigned

Continuation of Application No. 08/258,416  
filed June 10, 1994

Examiner: Unassigned

Filing Date: August 21, 2001

For: ADENOVECTOR PHARMACEUTICAL  
COMPOSITION


**SUBMISSION OF NUCLEOTIDE/AMINO ACID SEQUENCE DISCLOSURES AND  
STATEMENT UNDER 37 C.F.R. §§ 1.821-1.825**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In accordance with the requirements of 37 C.F.R. §§ 1.821-1.825, a sequence listing forms part of the disclosure of the instant patent application. A paper copy of a sequence listing has been inserted immediately prior to the claims in the patent application. A computer readable copy on a computer diskette, prepared by applicants with the use of the PatentIn v.1.0 software, is enclosed herewith. The undersigned hereby verifies that the contents of the paper and the computer readable copies are the same.

Respectfully submitted,

  
John Klyk, Jr., Registration No. 30,763  
One of the Attorneys for Applicants  
**LEYDIG, VOIT & MAYER, LTD.**  
Two Prudential Plaza, Suite 4900  
180 North Stetson  
Chicago, Illinois 60601-6780  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

Date: August 21, 2001

**PATENT**

Attorney Docket No. 213187

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Kovesdi et al. Group Art Unit: Unassigned

Continuation of Application No. 08/258,416  
filed June 10, 1994

Examiner: Unassigned

Filing Date: August 21, 2001

For: ADENOVECTOR PHARMACEUTICAL  
COMPOSITION

**SUBMISSION OF FORMAL DRAWINGS**


Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Applicants enclose herewith three (3) sheets of formal drawings and request that the same be made of record in the above-identified patent application.

The Assistant Commissioner is hereby authorized to charge any fees that may be required to Account No. 12-1216. A duplicate copy of this communication is enclosed for that purpose.

Respectfully submitted,

  
John Kofyk, Jr., Reg. No. 30763  
One of the Attorneys for Applicants  
**LEYDIG, VOIT & MAYER, LTD.**  
Two Prudential Plaza, Suite 4900  
180 North Stetson  
Chicago, Illinois 60601-6780  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

Date: August 21, 2001